HDA17 Antibody

Overview of HDAC7 Antibodies

HDAC7 antibodies are immunological tools designed to detect and study HDAC7, a protein critical for chromatin remodeling, transcriptional repression, and cellular differentiation. These antibodies are widely used in techniques such as:

• Western blotting (WB)

• Immunoprecipitation (IP)

• Immunofluorescence (IF)

• Immunohistochemistry (IHC)

Cancer Biology

• Breast Cancer: HDAC7 maintains stem-like cell populations by repressing cytokines (e.g., IGFBP6/7) and regulating histone H3K27 acetylation .

• Non-Small Cell Lung Cancer (NSCLC): HDAC7 stabilizes β-catenin via deacetylation, activating FGF18 to promote tumor growth and metastasis. High HDAC7/FGF18 co-expression correlates with poor prognosis .

• Epstein-Barr Virus (EBV) Latency: HDAC7 represses the BZLF1 gene, contributing to viral persistence .

Epigenetic Regulation

• HDAC7 deacetylates histones and non-histone targets (e.g., ALKBH5), influencing RNA methylation and cellular stress responses .

• In CHO cells, HDAC5 knockdown (using HDAC inhibitors) enhances recombinant monoclonal antibody production by modulating histone acetylation .

Validation and Characterization

HDAC7 antibodies require rigorous validation due to variability in specificity:

• ab12174: Validated in WB using HeLa and NIH3T3 lysates, with a predicted band size of 103 kDa .

• sc-74563: Confirmed reactivity in IF and ELISA, available in conjugated forms (HRP, FITC) for multiplex assays .

• Antibody Pair (10539-016): Includes capture (rabbit polyclonal) and detection (mouse monoclonal) antibodies for quantitative assays .

Common Pitfalls:

• Cross-reactivity with other HDAC isoforms (e.g., HDAC5 in CHO cells ).

• Batch-to-batch variability in polyclonal antibodies .

Therapeutic Implications

• HDAC Inhibitors: Compounds like suberoylanilide hydroxamic acid (SAHA) block HDAC7 activity, showing promise in breast and gastric cancers .

• Dual-Target Inhibitors: HDAC/LSD1 inhibitors enhance recombinant protein yields in biomanufacturing .

Future Directions

• Develop isoform-specific inhibitors to minimize off-target effects.

• Explore HDAC7’s role in immune evasion via B7-H1 upregulation in gastric cancer .